nach oben

Erschienen in:

01.12.2015 | Topic Review & Clinical Guidelines

Management of patients with recurrence of diffuse low grade glioma

A systematic review and evidence-based clinical practice guideline

verfasst von: Brian V. Nahed, Navid Redjal, Daniel J. Brat, Andrew S. Chi, Kevin Oh, Tracy T. Batchelor, Timothy C. Ryken, Steven N. Kalkanis, Jeffrey J. Olson

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2015

Einloggen, um Zugang zu erhalten

Abstract

Target population

These recommendations apply to adult patients with recurrent low-grade glioma (LGG) with initial pathologic diagnosis of a WHO grade II infiltrative glioma (oligodendroglioma, astrocytoma, or oligo-astrocytoma).

Pathology at recurrence

Question

Do pathologic and molecular characteristics predict outcome/malignant transformation at recurrence?

Recommendations

IDH status and recurrence

(Level III) IDH mutation status should be determined as LGGs with IDH mutations have a shortened time to recurrence. It is unclear whether knowledge of IDH mutation status provides benefit in predicting time to progression or overall survival.

TP53 status and recurrence

(Level III) TP53 mutations occur early in LGG pathogenesis, remain stable, and are not recommended as a marker of predisposition to malignant transformation at recurrence or other measures of prognosis.

MGMT status and recurrence

(Level III) Assessment of MGMT status is recommended as an adjunct to assessing prognosis as LGGs with MGMT promoter methylation are associated with shorter PFS (in the absence of TMZ) and longer post-recurrence survival (in the presence of TMZ), ultimately producing similar overall survival to LGGs without MGMT methylationThe available retrospective reports are conflicting and comparisons between reports are limited

CDK2NA status and recurrence

(Level III) Assessment of CDK2NA status is recommended when possible as the loss of expression of the CDK2NA via either methylation or loss of chromosome 9p is associated with malignant progression of LGGs.

Proliferative index and recurrence

(Level III) It is recommended that proliferative indices (MIB-1 or BUdR) be measured in LGGs as higher proliferation indices are associated with increased likelihood of recurrence and shorter progression free and overall survival.

1p/19q status and recurrence

There is insufficient evidence to make any recommendations.

Chemotherapy at recurrence

Question

What role does chemotherapy have in LGG recurrence?

Recommendations

Temozolomide and recurrence

(Level III) Temozolomide is recommended in the therapy of recurrent LGG as it may improve clinical symptoms. Oligodendrogliomas and tumors with 1p/19q co-deletion may derive the most benefit.

PCV and recurrence

(Level III) PCV is recommended in the therapy of LGG at recurrence as it may improve clinical symptoms with the strongest evidence being for oligodendrogliomas.

Carboplatin and recurrence

(Level III) Carboplatin is not recommended as there is no significant benefit from carboplatin as single agent therapy for recurrent LGGs.

Other treatments (Nitrosureas, Hydroxyurea/Imanitib, irinotecan, paclitaxel) and recurrence

There is insufficient evidence to make any recommendations. It is recommended that individuals with recurrent LGGs be enrolled in a properly designed clinical trial to assess these chemotherapeutic agents.

Radiation at recurrence

Question

What role does radiation have in LGG recurrence?

Recommendations

Radiation at recurrence with no previous irradiation

(Level III) Radiation is recommended at recurrence if there was no previous radiation treatment.

Re-irradiation at recurrence

(Level III) It is recommended that re-irradiation be considered in the setting of LGG recurrence as it may provide benefit in disease control.

Surgery at recurrence

There is insufficient evidence to make any specific recommendations. It is recommended that individuals with recurrent LGGs be enrolled in a properly designed clinical trial to assess the role of surgery at recurrence.

Juratli TA, Kirsch M, Robel K et al (2012) IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas. J Neurooncol 108(3):403–410CrossRefPubMed

Hartmann C, Hentschel B, Tatagiba M et al (2011) Molecular markers in low-grade gliomas: predictive or prognostic? Clin Cancer Res 17(13):4588–4599CrossRefPubMed

Thon N, Eigenbrod S, Kreth S et al (2012) IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer 118(2):452–460CrossRefPubMed

Ishii N, Tada M, Hamou MF et al (1999) Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 18(43):5870–5878CrossRefPubMed

Watanabe K, Sato K, Biernat W et al (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3(4):523–530PubMed

Kraus JA, Bolln C, Wolf HK et al (1994) TP53 alterations and clinical outcome in low grade astrocytomas. Genes Chromosomes Cancer 10(2):143–149CrossRefPubMed

Groenendijk FH, Taal W, Dubbink HJ et al (2011) MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation. J Neurooncol 101(3):405–417PubMedCentralCrossRefPubMed

Heesters MA, Koudstaal J, Go KG, Molenaar WM (2002) Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy. J Neurooncol 58(2):157–165CrossRefPubMed

Reifenberger J, Ring GU, Gies U et al (1996) Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol 55(7):822–831CrossRefPubMed

10.

Watanabe T, Katayama Y, Yoshino A et al (2007) Aberrant hypermethylation of p14ARF and O₆-methylguanine-DNA methyltransferase genes in astrocytoma progression. Brain Pathol 17(1):5–10CrossRefPubMed

11.

Laffaire J, Everhard S, Idbaih A et al (2011) Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro Oncol 13(1):84–98PubMedCentralCrossRefPubMed

12.

Idbaih A, Carvalho Silva R, Criniere E et al (2008) Genomic changes in progression of low-grade gliomas. J Neurooncol 90(2):133–140CrossRefPubMed

13.

Hoshi M, Yoshida K, Shimazaki K, Sasaki H, Otani M, Kawase T (1997) Correlation between MIB-1 staining indices and recurrence in low-grade astrocytomas. Brain Tumor Pathol 14(1):47–51CrossRefPubMed

14.

Ito S, Chandler KL, Prados MD et al (1994) Proliferative potential and prognostic evaluation of low-grade astrocytomas. J Neurooncol 19(1):1–9CrossRefPubMed

15.

Jung TY, Jung S, Moon JH, Kim IY, Moon KS, Jang WY (2011) Early prognostic factors related to progression and malignant transformation of low-grade gliomas. Clin Neurol Neurosurg 113(9):752–757CrossRefPubMed

16.

Jaeckle KA, Decker PA, Ballman KV et al (2011) Transformation of low grade glioma and correlation with outcome: an NCCTG database analysis. J Neurooncol 104(1):253–259CrossRefPubMed

17.

Chaichana KL, McGirt MJ, Laterra J, Olivi A, Quinones-Hinojosa A (2010) Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J Neurosurg 112(1):10–17CrossRefPubMed

18.

Taal W, Dubbink HJ, Zonnenberg CB et al (2011) First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response. Neuro Oncol 13(2):235–241PubMedCentralCrossRefPubMed

19.

Kesari S, Schiff D, Drappatz J et al (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15(1):330–337CrossRefPubMed

20.

Tosoni A, Franceschi E, Ermani M et al (2008) Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas. J Neurooncol 89(2):179–185CrossRefPubMed

21.

Kaloshi G, Benouaich-Amiel A, Diakite F et al (2007) Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology 68(21):1831–1836CrossRefPubMed

22.

Levin N, Lavon I, Zelikovitsh B et al (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O₆-methylguanine DNA methyltransferase protein expression. Cancer 106(8):1759–1765CrossRefPubMed

23.

Everaert E, Neyns B, Joosens E, Strauven T, Branle F, Menten J (2004) Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium. J Neurooncol 70(1):37–48CrossRefPubMed

24.

Pace A, Vidiri A, Galie E et al (2003) Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14(12):1722–1726CrossRefPubMed

25.

Quinn JA, Reardon DA, Friedman AH et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21(4):646–651CrossRefPubMed

26.

van den Bent MJ, Taphoorn MJ, Brandes AA et al (2003) Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European organization for research and treatment of cancer brain tumor group study 26971. J Clin Oncol 21(13):2525–2528CrossRefPubMed

27.

van den Bent MJ, Chinot O, Boogerd W et al (2003) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14(4):599–602CrossRefPubMed

28.

Kouwenhoven MC, Kros JM, French PJ et al (2006) 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment. Eur J Cancer 42(15):2499–2503CrossRefPubMed

29.

Chahlavi A, Kanner A, Peereboom D, Staugaitis SM, Elson P, Barnett G (2003) Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: preliminary results. J Neurooncol 61(3):267–273CrossRefPubMed

30.

Dubbink HJ, Taal W, van Marion R et al (2009) IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide. Neurology 73(21):1792–1795CrossRefPubMed

31.

Hoang-Xuan K, Capelle L, Kujas M et al (2004) Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22(15):3133–3138CrossRefPubMed

32.

Soffietti R, Ruda R, Bradac GB, Schiffer D (1998) PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43(5):1066–1073CrossRefPubMed

33.

van den Bent MJ, Kros JM, Heimans JJ et al (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch neuro-oncology group. Neurology 51(4):1140–1145CrossRefPubMed

34.

Friedman HS, Krischer JP, Burger P et al (1992) Treatment of children with progressive or recurrent brain tumors with carboplatin or iproplatin: a Pediatric Oncology Group randomized phase II study. J Clin Oncol 10(2):249–256PubMed

35.

Soffietti R, Nobile M, Ruda R et al (2004) Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study. Cancer 100(4):807–813CrossRefPubMed

36.

Friedman HS, Lovell S, Rasheed K, Friedman AH (1998) Treatment of adults with progressive oligodendroglioma with carboplatin (CBDCA): preliminary results. Writing committee for the brain tumor center at Duke. Med Pediatr Oncol 31(1):16–18CrossRefPubMed

37.

Kaloshi G, Sierra del Rio M, Ducray F et al (2010) Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide. J Neurooncol 100(3):439–441CrossRefPubMed

38.

Reardon DA, Desjardins A, Vredenburgh JJ et al (2012) Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. Cancer 118(19):4759–4767PubMedCentralCrossRefPubMed

39.

Chamberlain MC (2002) Salvage chemotherapy with CPT-11 for recurrent oligodendrogliomas. J Neurooncol 59(2):157–163CrossRefPubMed

40.

Taillibert S, Vincent LA, Granger B et al (2009) Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology 72(18):1601–1606CrossRefPubMed

41.

Chamberlain MC, Kormanik PA (1997) Salvage chemotherapy with paclitaxel for recurrent oligodendrogliomas. J Clin Oncol 15(12):3427–3432PubMed

42.

van den Bent MJ, Afra D, de Witte O et al (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366(9490):985–990CrossRefPubMed

43.

Karim AB, Afra D, Cornu P et al (2002) Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European organization for research and treatment of cancer study 22845 with the medical research council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52(2):316–324CrossRefPubMed

44.

Hanzely Z, Polgar C, Fodor J et al (2003) Role of early radiotherapy in the treatment of supratentorial WHO Grade II astrocytomas: long-term results of 97 patients. J Neurooncol 63(3):305–312CrossRefPubMed

45.

Combs SE, Ahmadi R, Schulz-Ertner D, Thilmann C, Debus J (2005) Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation. J Neurooncol 71(3):319–323CrossRefPubMed

46.

Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23(34):8863–8869CrossRefPubMed

47.

Shepherd SF, Laing RW, Cosgrove VP et al (1997) Hypofractionated stereotactic radiotherapy in the management of recurrent glioma. Int J Radiat Oncol Biol Phys 37(2):393–398CrossRefPubMed

48.

Hara A, Nishimura Y, Sakai N, Yamada H, Yanagawa S (1995) Effectiveness of intraoperative radiation therapy for recurrent supratentorial low grade glioma. J Neurooncol 25(3):239–243CrossRefPubMed

49.

McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohoff J (1992) Treatment and survival of low-grade astrocytoma in adults—1977–1988. Neurosurgery 31(4):636–642CrossRefPubMed

50.

Forsyth PA, Kelly PJ, Cascino TL et al (1995) Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful? J Neurosurg 82(3):436–444CrossRefPubMed

51.

Schmidt MH, Berger MS, Lamborn KR et al (2003) Repeated operations for infiltrative low-grade gliomas without intervening therapy. J Neurosurg 98(6):1165–1169CrossRefPubMed

52.

Steiger HJ, Markwalder RV, Seiler RW, Ebeling U, Reulen HJ (1990) Early prognosis of supratentorial grade 2 astrocytomas in adult patients after resection or stereotactic biopsy. An analysis of 50 cases operated on between 1984 and 1988. Acta Neurochir 106(3–4):99–105CrossRefPubMed

53.

Scopece L, Franceschi E, Cavallo G et al (2006) Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol 79(3):299–305CrossRefPubMed

54.

Brandes AA, Basso U, Vastola F et al (2003) Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study. Ann Oncol 14(12):1727–1731CrossRefPubMed

55.

Streffer J, Schabet M, Bamberg M, Grote EH, Meyerman R, Voigt K, Dicgans J, Weller M (2000) A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors. J Neurooncol 247(4):297–302

56.

Reyes-Mugica M, Rieger-Christ K, Ohgaki H, Ekstrand BC, Helie M, Kleinman G, Yahanda A, Fearon ER, Kleihues P, Reale MA (1997) Loss of DCC expression and glioma progression. Cancer Res 57(3):382–386

Titel: Management of patients with recurrence of diffuse low grade glioma
A systematic review and evidence-based clinical practice guideline
verfasst von: Brian V. Nahed
Navid Redjal
Daniel J. Brat
Andrew S. Chi
Kevin Oh
Tracy T. Batchelor
Timothy C. Ryken
Steven N. Kalkanis
Jeffrey J. Olson
Publikationsdatum: 01.12.2015
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2015
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-015-1910-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Management of patients with recurrence of diffuse low grade glioma

A systematic review and evidence-based clinical practice guideline

Abstract

Target population

Pathology at recurrence

Question

Recommendations

IDH status and recurrence

TP53 status and recurrence

MGMT status and recurrence

CDK2NA status and recurrence

Proliferative index and recurrence

1p/19q status and recurrence

Chemotherapy at recurrence

Question

Recommendations

Temozolomide and recurrence

PCV and recurrence

Carboplatin and recurrence

Other treatments (Nitrosureas, Hydroxyurea/Imanitib, irinotecan, paclitaxel) and recurrence

Radiation at recurrence

Question

Recommendations

Radiation at recurrence with no previous irradiation

Re-irradiation at recurrence

Surgery at recurrence

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Springer Medizin

Abstract

Target population

Pathology at recurrence

Question

Recommendations

IDH status and recurrence

TP53 status and recurrence

MGMT status and recurrence

CDK2NA status and recurrence

Proliferative index and recurrence

1p/19q status and recurrence

Chemotherapy at recurrence

Question

Recommendations

Temozolomide and recurrence

PCV and recurrence

Carboplatin and recurrence

Other treatments (Nitrosureas, Hydroxyurea/Imanitib, irinotecan, paclitaxel) and recurrence

Radiation at recurrence

Question

Recommendations

Radiation at recurrence with no previous irradiation

Re-irradiation at recurrence

Surgery at recurrence

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2015

The role of surgery in the management of patients with diffuse low grade glioma

Low grade glioma guidelines: Foreword

The role of initial chemotherapy for the treatment of adults with diffuse low grade glioma

Evidence-based clinical practice parameter guidelines for the treatment of adults with diffuse low grade glioma: introduction and methods

The role of neuropathology in the management of patients with diffuse low grade glioma

The role of imaging in the management of adults with diffuse low grade glioma

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie